9.245

0.59% -0.055

Intellia Therapeutics Inc (NTLA)

Overview News Price History Option Chain Financials Discussions Forecast

Intellia Therapeutics Inc stock is traded at $9.245, with a volume of 991.78K. It is down -0.59% in the last 24 hours and down -4.98% over the past month. Intellia Therapeutics is a gene-editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.

Previous Close:

$9.30

Open:

$9.27

24h Volume:

991.78K

Relative Volume:

0.13

Market Cap:

$1.07B

Revenue:

$52.86M

Net Income/Loss:

$-480.19M

P/E Ratio:

-1.9713

EPS:

-4.6899

Net Cash Flow:

$-421.82M

1W Performance:

+2.04%

1M Performance:

-4.98%

6M Performance:

+9.15%

1Y Performance:

-37.19%

1-Day Range:

$9.1512

$9.3951

1-Week Range:

$8.852

$9.95

52-Week Range:

$5.90

$28.25

Intellia Therapeutics Inc Stock (NTLA) Company Profile

Name

Intellia Therapeutics Inc

Sector

Healthcare (1133)

Industry

Biotechnology (634)

Phone

857-285-6200

Address

40 ERIE STREET, CAMBRIDGE, MA

Employee

598

Twitter

@intelliatweets

Next Earnings Date

2024-11-07

Latest SEC Filings

NTLA's Discussions on Twitter

Compare NTLA with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
NTLA Intellia Therapeutics Inc	9.2477	1.08B	52.86M	-480.19M	-421.82M	-4.6899
VRTX Vertex Pharmaceuticals Inc	436.50	110.88B	11.74B	3.68B	3.34B	14.19
REGN Regeneron Pharmaceuticals Inc	712.39	72.79B	14.25B	4.58B	3.88B	41.77
ARGX Argen X Se Adr	895.11	54.76B	3.06B	1.28B	447.35M	19.67
ALNY Alnylam Pharmaceuticals Inc	408.64	54.85B	3.21B	43.57M	221.36M	0.2405
INSM Insmed Inc	194.58	41.41B	447.02M	-1.18B	-906.14M	-6.1812

Intellia Therapeutics Inc Stock (NTLA) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Nov-12-25	Downgrade	Wolfe Research	Outperform → Peer Perform
Nov-11-25	Downgrade	Evercore ISI	Outperform → In-line
Nov-07-25	Downgrade	JP Morgan	Neutral → Underweight
Oct-28-25	Downgrade	Bernstein	Outperform → Mkt Perform
Oct-28-25	Downgrade	RBC Capital Mkts	Outperform → Sector Perform
Oct-27-25	Downgrade	Guggenheim	Buy → Neutral
Oct-27-25	Downgrade	William Blair	Outperform → Mkt Perform
Oct-06-25	Upgrade	Citizens JMP	Mkt Perform → Mkt Outperform
Apr-21-25	Upgrade	Wolfe Research	Peer Perform → Outperform
Mar-05-25	Initiated	H.C. Wainwright	Buy
Feb-28-25	Downgrade	Goldman	Neutral → Sell
Feb-28-25	Downgrade	JP Morgan	Overweight → Neutral
Jan-27-25	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Feb-23-24	Downgrade	Goldman	Buy → Neutral
Feb-15-24	Initiated	Wolfe Research	Peer Perform
Apr-13-23	Initiated	Canaccord Genuity	Buy
Mar-21-23	Initiated	Bernstein	Outperform
Mar-14-23	Upgrade	BMO Capital Markets	Market Perform → Outperform
Feb-01-23	Initiated	Cantor Fitzgerald	Overweight
Jan-24-23	Upgrade	Citigroup	Sell → Neutral
Jan-19-23	Downgrade	JMP Securities	Mkt Outperform → Mkt Perform
Oct-11-22	Initiated	Morgan Stanley	Overweight
Sep-21-22	Initiated	JP Morgan	Overweight
Sep-01-22	Initiated	Citigroup	Sell
Jun-17-22	Initiated	BMO Capital Markets	Market Perform
Jun-16-22	Initiated	BofA Securities	Buy
Apr-28-22	Initiated	Credit Suisse	Outperform
Feb-18-22	Initiated	William Blair	Outperform
Feb-07-22	Upgrade	Oppenheimer	Perform → Outperform
Jan-31-22	Initiated	Cowen	Outperform
Jan-07-22	Initiated	Piper Sandler	Overweight
Oct-05-21	Initiated	Guggenheim	Buy
Sep-24-21	Initiated	Stifel	Buy
Jun-28-21	Reiterated	H.C. Wainwright	Buy
Jun-11-21	Initiated	H.C. Wainwright	Buy
May-07-21	Upgrade	ROTH Capital	Neutral → Buy
May-04-21	Initiated	RBC Capital Mkts	Outperform
Mar-04-21	Initiated	JMP Securities	Mkt Outperform
Dec-22-20	Downgrade	Robert W. Baird	Outperform → Neutral
Oct-27-20	Initiated	Truist	Buy
Oct-14-20	Initiated	Wells Fargo	Overweight
Sep-18-20	Initiated	Goldman	Buy
Feb-28-20	Upgrade	Oppenheimer	Perform → Outperform
Feb-14-20	Downgrade	Wedbush	Outperform → Neutral
Nov-01-19	Upgrade	Raymond James	Mkt Perform → Outperform
Jul-09-19	Initiated	Robert W. Baird	Outperform
Jun-10-19	Initiated	ROTH Capital	Neutral
May-03-19	Upgrade	Wedbush	Neutral → Outperform
Apr-12-19	Initiated	Evercore ISI	Outperform
Nov-02-18	Downgrade	Wedbush	Outperform → Neutral
Oct-29-18	Initiated	Credit Suisse	Neutral
Sep-21-18	Initiated	Raymond James	Mkt Perform
May-15-18	Upgrade	Chardan Capital Markets	Neutral → Buy
Mar-08-18	Initiated	JMP Securities	Mkt Outperform
Nov-01-17	Reiterated	Jefferies	Buy
Jun-22-17	Resumed	Jefferies	Buy
Mar-28-17	Initiated	Chardan Capital Markets	Buy
Aug-05-16	Upgrade	Jefferies	Hold → Buy

View All

Intellia Therapeutics Inc Stock (NTLA) Latest News

Dec 08, 2025

Volume Recap: Will Intellia Therapeutics Inc. stock remain a Wall Street favoriteJuly 2025 Action & Free Weekly Watchlist of Top Performers - BỘ NỘI VỤ

Dec 08, 2025

Intellia Therapeutics (NASDAQ:NTLA) Nasdaq Index Expands Genetic Research - Kalkine Media

Dec 08, 2025

Intellia Therapeutics (NASDAQ:NTLA) Stock Rating Upgraded by Wall Street Zen - MarketBeat

Dec 08, 2025

Dec 07, 2025

Would You Still Hold Intellia Therapeutics Stock If It Fell Another 30%? - Trefis

Dec 07, 2025

Dec 06, 2025

Investors who Lost Money on Intellia Therapeutics, Inc. (NTLA) Should Contact Levi & Korsinsky About Pending Class ActionNTLA - 28/22 News

Dec 06, 2025

Schroder Investment Management Group Increases Stock Holdings in Intellia Therapeutics, Inc. $NTLA - MarketBeat

Dec 06, 2025

Dec 05, 2025

Intellia Focuses on Pipeline Development Amid Stiff Competition - MSN

Dec 05, 2025

Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times

Dec 05, 2025

Intellia Therapeutics (NASDAQ: NTLA) issues 12,600 inducement RSUs to three new employees - Stock Titan

Dec 05, 2025

Will Intellia Therapeutics Inc. (38I) stock benefit from mergersJuly 2025 Momentum & Weekly Stock Performance Updates - Newser

Dec 05, 2025

How analysts revise price targets for Intellia Therapeutics Inc. (38I) stockWeekly Risk Report & Accurate Technical Buy Alerts - Newser

Dec 05, 2025

Will Intellia Therapeutics Inc. (38I) stock recover faster than industryMarket Volume Summary & Technical Pattern Alert System - Newser

Dec 05, 2025

What dividend safety rating applies to Intellia Therapeutics Inc. (38I) stockMarket Sentiment Report & AI Based Trade Execution Alerts - Newser

Dec 05, 2025

Dec 04, 2025

Suumaya Corporation Limited Included in Top Momentum ScanFibonacci Extensions & Free Daily Stock Hotspot Analysis - earlytimes.in

Dec 04, 2025

Why analysts maintain buy rating on Intellia Therapeutics Inc. (38I) stockJuly 2025 Short Interest & Safe Capital Growth Trade Ideas - Newser

Dec 04, 2025